Accession Therapeutics

With its stealth virus platform technology, Trocept,
Accession Therapeutics is focused on treating some of the most intractable and widespread forms of cancer.

[Accession Therapeutics @AccessionTX]

Looking ahead, we’ll be at #BioEquityEurope (Prague, 4-6 May) and #PEGSummit (Boston, 11-15 May).

Stephanie Bewick and David Krige will attend BioEquity Europe
📍 Presentation | North Hall | 10:15am | 5 May

Dave Cole will attend PEGS Boston
🎙️ Chair | 8:30am | 12 May
🧬 Presentation | 9:05am | 12 May

🔗 Learn more: https://t.co/7BDMadJG6d

[Accession Therapeutics @AccessionTX]

A brilliant day bringing the team together for our inaugural company conference.

A chance to reflect on our growth over the past 4.5 years, from a small founding team to 45 people with our lead programme now in the clinic, and to focus on what comes next.

A real privilege to work with such collaborative and talented people.

#Biotech #Teamwork #Strategy #LifeSciences

[Accession Therapeutics @AccessionTX]

A great couple of weeks for the Accession Therapeutics team at BIO-Europe Spring, LSX Europe and the Advanced Therapies Congress.

Valuable time spent reconnecting with potential partners, industry peers and hearing first-hand insights from investors.

🔗 Learn more: https://t.co/Xb5W4vje9r

#BIOEuropeSpring #LSXEurope #AdvancedTherapies26

[Accession Therapeutics @AccessionTX]

Join our Chief Development Officer, David Krige, at the World Clinical Biomarkers & Companion Diagnostics Summit Europe in London next week where he is chairing a session on Biomarker Discovery & Translation on Tuesday 31st March.

#CBCDxEurope #Biomarkers #PrecisionMedicine

[Accession Therapeutics @AccessionTX]

We’re pleased to announce Accession Therapeutics has been awarded €7.5m in grant funding from Horizon Europe.

The grant will fund an expansion study of the ongoing ATTEST Phase 1 clinical trial of TROCEPT-01 (ATTR-01) in solid tumours to further assess clinical efficacy and safety.

TROCEPT-01 is a first-in-class immunotherapy designed to bypass normal tissue, target αvβ6 integrin on carcinomas and express a potent checkpoint inhibitor within tumours.

🔗 Read more in the press release: https://t.co/YXHcVcOWns

[Accession Therapeutics @AccessionTX]

Heading to Spring Innovation Week 2026 in Lisbon.

Our CBO Stephanie Bewick and Head of Research Dave Cole will be at BIO-Europe Spring (23-25 March) and LSX Europe (25-26 March) connecting with potential partners.

Watch the short video to learn more about Accession Therapeutics’ platform.

#BIOEuropeSpring #LSXEurope #Partnering #Immunotherapy

[Accession Therapeutics @AccessionTX]

Great discussions at #IO360 around emerging immuno-oncology approaches. Thank you to everyone who visited our poster stands to learn more about the TROCEPT platform and the ATTEST study.

TROCEPT-01 (ATTR-01) is engineered to target αvβ6-positive tumours and deliver an anti-PD-L1 payload locally following IV administration – our first clinical programme from the platform.

🔗 Learn more: https://t.co/Xb5W4vje9r

#ImmunoOncology #Biotech #ClinicalTrials #Innovation

[Accession Therapeutics @AccessionTX]

Our CBO, Stephanie Bewick, and CDO, David Krige, will be attending #IO360 in Boston (10–12 Feb).

David will present two posters showcasing preclinical and clinical research from our TROCEPT platform and ongoing Phase 1 ATTEST study of TROCEPT-01 in solid tumours.

🔗 Learn more: https://t.co/Xb5W4vje9r

#ImmunoOncology #Biotech

[Accession Therapeutics @AccessionTX]

Today on #WorldCancerDay, Accession Therapeutics stands alongside the global community in supporting patients and their families and advancing the fight against cancer.

With approximately 1 in 5 people worldwide developing cancer during their lifetime, the need for innovative treatment approaches remains critical. We are committed to advancing next-generation immunotherapies with the potential to improve patient outcomes and expand treatment options.

[Accession Therapeutics @AccessionTX]

That’s a wrap on #JPMHC26! Thanks to everyone who connected with Accession Therapeutics during a busy and energising week in San Francisco.

Our CBO Stephanie Bewick and COO Jez Gerry enjoyed meeting industry peers and potential partners across #JPMHC26, #BiotechShowcase and #Sachs_OIF.

Great conversations highlighting the continued interest in differentiated oncology approaches and the power of collaboration.

Looking forward to continuing the discussions.

#BiotechSisterhood #WearPink #Partnering #BusinessDevelopment #Oncology

[Accession Therapeutics @AccessionTX]

Attending #JPM2026? Accession’s CBO Stephanie Bewick and COO Jez Gerry will be in San Francisco for a busy week, including:

· Sachs Oncology Innovation Forum (10 Jan)
· J.P. Morgan Healthcare Conference (12–15 Jan)
· Biotech Showcase (12–14 Jan)

Get in touch to arrange a meeting.

#BiotechShowcase #Sachs_OIF #Partnering #Biotech #BusinessDevelopment #LifeSciences

[Accession Therapeutics @AccessionTX]

Accession Therapeutics will be participating in the Sachs 11th Annual Oncology Innovation Forum on 10 January 2026.

🗣️ COO Jez Gerry joins the Advanced Immunotherapies Panel plenary session
🧬 CBO Stephanie Bewick presents our strategy and lead programme TROCEPT-01 (ATTR-01), now in Phase 1 (ATTEST study)

Join us in San Francisco or explore the science behind our TROCEPT platform 👉 https://t.co/Xb5W4vje9r

#Sachs_OIF #Biotech #ImmunoOncology #ATTEST #TROCEPT

[Accession Therapeutics @AccessionTX]

In a new @BiotechTV interview, CEO Bent Jakobsen expands on the unique value of our tumour-targeted viral delivery technology and discusses highlights from a strong year at Accession Therapeutics – including advancement of our lead programme into the clinic and today’s financing – as we continue to focus on demonstrating the full potential of the TROCEPT platform.

🎥 Watch the full interview here: https://t.co/OgUNClpWQy

#Biotech #ImmunoOncology #TROCEPT #ATTESTstudy

[BiotechTV @BiotechTV]

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Oxford, UK based @AccessionTX raised $40M from existing investors today to further develop its precision viral delivered immunotherapies. The first program induces cancer cells to make PD-L1.

Full video: https://t.co/f6QkbnBuMK

[Accession Therapeutics @AccessionTX]

We’re pleased to announce that Accession Therapeutics has completed a £30.5 million ($40 million USD) fundraise to advance the development of our TROCEPT platform.

The investment will support the generation of full clinical data from our ongoing Phase 1 study of TROCEPT-01 (ATTR-01), our lead programme in advanced solid tumours, and progression of our second programme, TROCEPT-02 (ATTR-02), into the clinic.

We thank our investors for their continued support.

🔗 Read more in the press release: https://t.co/LdTkBlWJjd

#Biotech #ImmunoOncology #CancerResearch #ClinicalTrials #TROCEPT

[Accession Therapeutics @AccessionTX]

Great to have our Head of Research David Cole represent us at #PEGSEurope last week.

🎙️In the Next-Gen Viral Immunotherapies track, Dave presented our TROCEPT platform – designed for IV, tumour-selective delivery – and shared an update on our lead clinical programme.

🧬 He also chaired a session on innovative CAR therapies and led a roundtable on overcoming the limits of current cancer immunotherapies. Key takeaway: combination approaches + collaboration will be essential.

Thank you to the organisers and all who joined the discussions.

🔗 Learn more about our platform: https://t.co/Xb5W4vje9r

#ImmunoOncology #NextGenImmunotherapy #CancerResearch #Biotech #TROCEPT

[Accession Therapeutics @AccessionTX]

🔬Our tumour-selective viral vector is engineered to bypass normal tissue, target αvβ6 integrin on carcinomas and express a potent checkpoint inhibitor within tumours.

👀See how our virus selectively replicates in cancer cells and releases immune payloads to turn cold tumours hot. https://t.co/RgaQvue2oc

#Biotech #ClinicalDevelopment #SolidTumours

[Accession Therapeutics @AccessionTX]

🎬What’s behind the ATTEST trial? Accession Therapeutics CEO Bent Jakobsen and Lead Investigator Prof. Adel Samson @UniversityLeeds discuss the science driving our first-in-human study of TROCEPT-01.

🎥 Watch now https://t.co/h1S3rp1tco

#Biotech #ImmunoOncology #CancerTrials